Related Experiment Video

Updated: Aug 20, 2026

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Glycosylated hemoglobin in diabetic and nondiabetic dogs

E A Mahaffey, L M Cornelius

    Journal of the American Veterinary Medical Association
    |March 15, 1982
    PubMed

    Insights

    Glycosylated hemoglobin (HbA1) measurement can help monitor canine diabetes mellitus. Diabetic dogs showed significantly higher HbA1 levels, indicating its value in tracking therapy effectiveness.

    Area of Science:

    • Veterinary Medicine
    • Endocrinology
    • Clinical Pathology

    Background:

    • Glycosylated hemoglobin (HbA1) reflects long-term glycemic control.
    • Accurate monitoring is crucial for managing canine diabetes mellitus.

    Purpose of the Study:

    • To evaluate the utility of HbA1 measurement in assessing glycemic control in dogs.
    • To compare HbA1 levels across diabetic, nondiabetic hospitalized, and healthy dogs.

    Main Methods:

    • HbA1 levels were quantified in three distinct canine groups: diabetic (n=16), nondiabetic hospitalized (n=40), and healthy colony dogs (n=16).
    • Statistical analysis was performed to compare mean HbA1 values between groups.

    Main Results:

    • Mean HbA1 values were 9.63% (diabetic), 6.43% (nondiabetic hospitalized), and 5.62% (healthy colony dogs).
    • Significant differences were observed between all groups (P<0.05), with diabetic dogs exhibiting the highest levels.
    • 15 of 16 diabetic dogs had HbA1 concentrations exceeding 7.5%.

    Conclusions:

    • HbA1 measurement is a valuable tool for monitoring therapeutic efficacy in canine diabetes mellitus.
    • Elevated HbA1 levels are indicative of poor glycemic control in diabetic dogs.

    More Related Videos

    Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)08:13

    Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

    Published on: January 7, 2018

    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

    Published on: November 29, 2024

    Related Concept Videos

    Proteoglycans01:05

    Proteoglycans

    Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
    Diabetes Mellitus: Type 2 and Gestational01:22

    Diabetes Mellitus: Type 2 and Gestational

    Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
    Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

    Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

    Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
    Hypoglycemia01:26

    Hypoglycemia

    Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
    Hyperglycemia01:29

    Hyperglycemia

    Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...